A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non-Hodgkin’s Lymphoma

This study is a multicenter, non-randomized, single arm, open-label clinical trial in patients with R/R NHL, a disease that is classified into highly aggressive lymphoma, invasive lymphoma and inert lymphoma. Highly invasive NHL includes Burkitt lymphoma (BL), lymphoblastic lymphoma (LBL), high-grade B-cell lymphoma, as well as other types of lymphoma. Invasive NHL includes diffuse large B-cell lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma. Inert NHL includes follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

View Clinical Trial

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

This study is a multi-center, non-randomized, single-arm, open-label clinical trial in patients with R/R plasma cell tumors.

View Clinical Trial

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

This study is a multi-center, non-randomized, single-arm, open-label clinical trial in patients with R/R Hodgkin’s lymphoma.

View Clinical Trial

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

This is an open-label, single-arm, prospective, clinical study to evaluate efficacy and safety of an autologous CAR T-cell injection for the treatment of recurrent or refractory hematopoietic and lymphoid tissue tumors in children.

View Clinical Trial

CAR-T for Children with Relapsed and Refractory Acute Lymphoblastic Leukemia

Open, uncontrolled, multicenter clinical trial in which CAR-T will be administered to children with acute lymphoblastic leukemia to explore the effect of CAR-T intervention time on the duration of complete remission and further verify the long-term safety and efficacy of CAR-T treatment.

View Clinical Trial

Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

This is an open-label, single-arm, clinical study to evaluate efficacy and safety of anti-CD19 CAR T-cells in the treatment of recurrent or refractory B-ALL.

View Clinical Trial

Immunotherapy with BCMA CAR-T Cells in Treating Patients with Relapsed or Refractory Multiple Myeloma

Open-label, single-arm study to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma.

View Clinical Trial

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Open-label, single-arm study in patients with relapsed or refractory non-Hodgkin's lymphoma to evaluate the safety and efficacy of SL1904B.

View Clinical Trial

Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of R/R Acute B Lymphocytic Leukemia

This is an open, two-arm, masked, Phase I clinical study to evaluate efficacy and safety of two different chimeric antigen receptor T cell immunotherapies (Sen_1904A and Senl_1904B) targeting CD19 for the treatment of acute lymphocytic leukemia.

View Clinical Trial

Study Evaluating Safety and Efficacy of CAR T-Cells Targeting CD123 in Patients with Acute Myelocytic Leukemia 

This is an open, single-arm, Phase I clinical study to evaluate the efficacy and safety of chimeric antigen receptor T-cell immunotherapy (CAR-T) targeting CD123 for the treatment of acute myelocytic leukemia.

View Clinical Trial

CAR T-Cells in Treating Patients with Relapsed or Refractory NHL

This is an open, single-arm, Phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) for the treatment of non-Hodgkin's lymphoma.

View Clinical Trial

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

This is an open, single-arm, Phase I/Phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) for the treatment of R/R adult acute lymphoblastic leukemia bridging to allogeneic hematopoietic stem cell transplantation.

View Clinical Trial

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia Using CD7-Specific CAR T-Cells

This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR T-Cells for the treatment of recurrent or refractory T-cell acute lymphoblastic leukemia.

View Clinical Trial

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients with Solid Tumors

This is an open-labeled, single-armed and prospective Phase 1 study in patients with advanced malignant solid tumors to test the safety and efficacy of SL22P autologous CAR - T/CAR-TILs. The aim of the study is to evaluate the safety and efficacy of SL22P CAR-T cells, including the adverse reaction, pharmacokinetics, and the outcomes of patients.

View Clinical Trial

Safety and Efficacy Study of CD22 CAR T-Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22 CAR T-cells for the treatment of recurrent or refractory B-ALL.

View Clinical Trial